Purpose Despite the fact that most gastroenteropancreatic neuroendocrine tumors (GEPNETs)
are slowgrowing, median overall survival (OS) in patients with liver metastases is 2 to 4 …

Purpose There are few treatment options for patients with metastasized or inoperable endocrine
gastroenteropancreatic (GEP) tumors. Chemotherapy can be effective, but the response …

The somatostatin analogue [DOTA 0 ,Tyr 3 ]octreotate has a nine-fold higher affinity for the
somatostatin receptor subtype 2 as compared with [DOTA 0 ,Tyr 3 ]octreotide. Also, labelled …

As scintigraphy with [ 111 In-DTPA 0 ]octreotide has become a standard technique in
analysing somatostatin receptor-receptor positive lesions such as neuroendocrine tumours, a …

In vivo somatostatin receptor-mediated scintigraphy has proven to be a valuable method for
the visualisation of neuroendocrine tumours and their metastases. A new application is the …

Therapy using the radiolabeled somatostatin analog [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate (
177 Lu-octreotate) (DOTA is 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic …

Purpose Adequate dosimetry is mandatory for effective and safe peptide receptor radionuclide
therapy (PRRT). Besides the kidneys, the bone marrow is a potentially dose-limiting organ…

Purpose In peptide receptor radionuclide therapy (PRRT), the bone marrow (BM) is one of
the dose-limiting organs. The accepted dose limit for BM is 2 Gy, adopted from 131 I treatment…

Purpose After peptide receptor radionuclide therapy (PRRT), renal toxicity may occur, particular
in PRRT with 90 Y-labelled somatostatin analogues. Risk factors have been identified …

Quality Control The radioactivitiesin the fractionseluted from SEP-PAK Cl8 were measured
in a dose calibrator (VDC, 202, Veenstra, Joure, The Netherlands) under similar geometric …